Stockscreener 앱 받기
9.20
1.32%
0.12
전일 마감가:
$9.08
열려 있는:
$9.12
하루 거래량:
3.01M
Relative Volume:
2.12
시가총액:
$437.72M
수익:
$91.06M
순이익/손실:
$-503.14M
주가수익비율:
-1.0965
EPS:
-8.39
순현금흐름:
$-424.74M
1주 성능:
-0.86%
1개월 성능:
+40.89%
6개월 성능:
+49.84%
1년 성능:
-13.37%
1일 변동 폭
$9.105
$9.22
1주일 범위
$9.04
$9.28
52주 변동 폭
$4.62
$13.47
Sage Therapeutics Inc Stock (SAGE) Company Profile
명칭
Sage Therapeutics Inc
전화
617-299-8380
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
SAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
9.20 | 437.72M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-11 | 재개 | BofA Securities | Underperform |
| 2024-11-21 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-29 | 개시 | Citigroup | Sell |
| 2024-05-29 | 개시 | Robert W. Baird | Neutral |
| 2024-04-17 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-08-08 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-08-08 | 다운그레이드 | Needham | Buy → Hold |
| 2023-08-07 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-08-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-08-07 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-08-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-03-31 | 개시 | Berenberg | Hold |
| 2021-11-02 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-04-07 | 개시 | Piper Sandler | Overweight |
| 2021-02-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-02-25 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 재개 | Raymond James | Mkt Perform |
| 2021-01-22 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | 재확인 | H.C. Wainwright | Neutral |
| 2020-09-11 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-08-10 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-04-08 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-03-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-28 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-06 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-12-05 | 재확인 | Guggenheim | Buy |
| 2019-12-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-10-30 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-23 | 개시 | Wedbush | Outperform |
| 2019-04-25 | 개시 | Jefferies | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-11 | 개시 | Oppenheimer | Outperform |
모두보기
Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus
SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus
SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India
Supernus enters depression drug market with up to $795 million Sage deal - Reuters
Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga
Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks
Supernus to buy Sage for up to $795 million - Axios
Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News
Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener
Supernus strikes deal to buy Sage Therapeutics - The Business Journals
After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum
SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada
Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com
After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston
Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals
Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus
Sage Therapeutics Inc (SAGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):